AI-generated · cited to primary sources · not investment advice
Laurus Labs (540222) Oct 2025 Filing Analysis
Does management do what it says?
EBITDA margins saw a massive expansion of 1,080 bps in H1 FY26 compared to H1 FY25, reaching 25.4%. (4 exceeded, 1 met across 5 tracked commitments)
“It will be closer to INR1,000 crores. We invested about INR480 crores in H1, and we expect to invest similar amount in H2 as well.”
Management confirmed that groundbreaking for the LB 4 Vizag facility occurred in June 2025. (2 met across 2 tracked commitments)
“Fermentation manufacturing site (Vizag) build up on track as planned - expect to commence operations by 2026 end”
The company reports that demand has been met with over 500 infusions as of September 2025, implying the capacity is operational. (1 met, 1 revised across 2 tracked commitments)
“2nd GMP facility (Navi Mumbai) commissioning expected by Jan’26 (to add 2,500 annual treatment capacity)”
Management proposes to invest over US $600 million in pharmaceutical manufacturing and R&D over the next 8 years. — target: >US $600mn
“Propose to invest >US $600mn in Pharma manufacturing & R&D investments focused across scale / technology over next several years”
See the full cited Management analysis of Laurus Labs
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.